Filing Overview
Unicycive Therapeutics, Inc. filed a Form 8-K on March 14, 2024, reporting transactions entered into on March 13, 2024, under Items 1.01, 3.02, 5.03 and 9.01. The filing concerns a preferred-stock exchange, amended warrants and related amendments to the Company’s capitalization documents. It does not report quarterly or annual operating results.
Business Context and Capital Structure
The Company exchanged 43,649,000 outstanding Series A-2 Preferred Stock shares held by accredited investors for 21,388.01 shares of newly designated Series A-2 Prime Preferred Stock. The Company also amended and restated outstanding warrants and eliminated its prior Series A-1 through Series A-5 preferred-stock designations.
The amended certificate of designation authorized 21,400 Series A-2 Prime, 25,900 Series A-3, 25,700 Series A-4 and 51,600 Series A-5 preferred shares, each with a stated value of $1,000 per share.
Key Financial and Securities Terms
- No revenue, profit, cash flow, margin, debt or liquidity figures are provided in this filing.
- Amended Tranche A warrants cover 25,840.3122 Series A-3 preferred shares, reduced from 47,852,430 shares under the original warrants.
- Amended Tranche B warrants cover 25,666.30154 Series A-4 preferred shares, reduced from 43,502,206 shares.
- Amended Tranche C warrants cover 51,506.61294 Series A-5 preferred shares, reduced from 69,603,581 shares.
- The amended warrants permit fractional preferred shares and set an exercise price of $1,000 per preferred share. The aggregate exercise price, common-stock conversion amounts and exercise periods were stated not to change.
- Conversion prices are $0.49 per common share for Series A-2 Prime, $0.54 for Series A-3, $0.59 for Series A-4 and $0.74 for Series A-5, subject to the certificate’s limitations.
- Preferred stock generally participates in dividends and liquidation distributions on an as-converted basis and votes with common stock on an as-converted basis, subject to stated limitations.
Material Changes Versus Prior Terms
- Existing Series A-2 Preferred Stock was exchanged for Series A-2 Prime Preferred Stock.
- Original Series A-1 through Series A-5 preferred-stock designations were eliminated, effective 12:01 a.m. Eastern Time on March 14, 2024.
- The amended Series A preferred-stock designation became effective at 6:01 a.m. Eastern Time on March 14, 2024.
- Warrant share amounts were substantially reduced and fractional-share issuance was added, while the filing states that aggregate exercise price, conversion amounts and exercise periods did not change.
Guidance, Risks and Unusual Items
The filing provides no financial guidance or operating outlook. The securities were issued without registration under exemptions including Section 4(a)(2), Rule 3(a)(9) and, for underlying securities where applicable, Rule 506. The transactions may affect future voting power, preferred-stock rights and potential common-stock dilution upon conversion or warrant exercise.
The summaries in the Form 8-K are qualified by the full Exchange Agreement, amended certificate of designation and amended warrant documents filed as exhibits. The filing does not provide a clear aggregate number of common shares issuable upon all conversions and warrant exercises beyond the stated conversion prices and terms.
Investor Verification Checklist
- Review the Exchange Agreement and amended certificate of designation for conversion limitations, voting provisions, liquidation treatment and other investor rights.
- Reconcile the exchanged 43,649,000 old preferred shares with the 21,388.01 new Series A-2 Prime shares.
- Confirm the outstanding warrant balances, exercise periods and aggregate potential common-stock issuance.
- Assess the potential dilution from conversion of all Series A preferred stock and exercise of the amended warrants.
- Verify the effective dates and legal effect of the Certificates of Elimination and the amended certificate of designation.